About this trial
The investigators' pre-clinical study confirms the positive effects of combined treatment (VT + HMB) on reducing fat-to-lean tissue ratio, intramuscular fat infiltration and increasing muscle strength in sarcopenia animal model. The results showed that fat mass could be decreased by \~32%, while histology Oil Red O staining indicated a decrease of fat by almost 60%; in contrast, lean muscle mass increased by \~14%. On muscle strength, combined treatment increased twitch force, tetanic force and grip strength by \~30-66%. These in vivo results are very encouraging and the investigators should explore its potential in clinical translation. As VT and HMB supplement have been commercially available and their compliance rates are satisfactory, they can be translated to clinical application easily. The investigators' next step is to confirm its clinical efficacy, so that sarcopenia becomes a new indication of VT and HMB. The hypothesis is that combined treatment of VT and HMB can retard the progression of sarcopenia in human, in terms of muscle mass, muscle strength and performance.
Eligibility criteria
Qualifiers
Subjects aged 60 years or above
Subjects failed in AWGS algorithm
skeletal muscle mass by BIA (male at <7.0 kg/m², female at <5.7 kg/m²), and
handgrip strength (male at <28 kg, female at <18kg), and/or
Disqualifiers
Subjects with pathological bone diseases
Subjects with chronic inflammatory condition (e.g. rheumatoid arthritis)
Subjects with neurological problems
Subjects receiving regular exercise
Trial design
Treatments tested in this trial
- Low-magnitude High-frequency Vibration
- β-hydroxy β-methylbutyrate (HMB) supplement
- Protein supplement
Treatment groups
Sponsors and collaborators
Chinese University of Hong Kong
Lead sponsor
Abbott
Collaborator